Enveric Biosciences (NASDAQ:ENVB) Stock Rating Upgraded by Wall Street Zen

Enveric Biosciences (NASDAQ:ENVB) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Enveric Biosciences Price Performance

Shares of ENVB traded down $0.08 during midday trading on Friday, hitting $1.35. 76,159 shares of the company traded hands, compared to its average volume of 205,692. Enveric Biosciences has a one year low of $1.26 and a one year high of $17.64. The firm has a market cap of $4.97 million, a P/E ratio of -0.06 and a beta of 1.15. The stock has a 50-day moving average of $1.94 and a 200-day moving average of $2.58.

Enveric Biosciences (NASDAQ:ENVB) last issued its quarterly earnings data on Friday, May 15th. The company reported ($1.08) EPS for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.